Oncolytic Reovirus in Canine Mast Cell Tumor

Chung Chew Hwang1, Saori Umeki1, Masahito Kubo2, Toshiharu Hayashi2, Hiroshi Shimoda3, Masami Mochizuki4, Ken Maeda3, Kenji Baba5, Hiroko Hiraoka5, Matt Coffey6, Masaru Okuda1,7,8, Takuya Mizuno1,7,8*

1 Laboratory of Veterinary Internal Medicine, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan, 2 Laboratory of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan, 3 Laboratory of Veterinary Microbiology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan, 4 Emerging Infectious Diseases, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan, 5 Yamaguchi University Animal Medical Center, Yamaguchi, Japan, 6 Oncolytics Biotech Inc., Calgary, Alberta, Canada, 7 Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan, 8 Biomedical Science Center for Translational Research, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan

Abstract

The usage of reovirus has reached phase II and III clinical trials in human cancers. However, this is the first study to report the oncolytic effects of reovirus in veterinary oncology, focusing on canine mast cell tumor (MCT), the most common cutaneous tumor in dogs. As human and canine cancers share many similarities, we hypothesized that the oncolytic effects of reovirus can be exploited in canine cancers. The objective of this study was to determine the oncolytic effects of reovirus in canine MCT in vitro, in vivo and ex vivo. We demonstrated that MCT cell lines were highly susceptible to reovirus as indicated by marked cell death, high production of progeny virus and virus replication. Reovirus induced apoptosis in the canine MCT cell lines with no correlation to their Ras activation status. In vivo studies were conducted using unilateral and bilateral subcutaneous MCT xenograft models with a single intratumoral reovirus treatment and apparent reduction of tumor mass was exhibited. Furthermore, cell death was induced by reovirus in primary canine MCT samples in vitro. However, canine and murine bone marrow-derived mast cells (BMCMC) were also susceptible to reovirus. The combination of these results supports the potential value of reovirus as a therapy in canine MCT but warrants further investigation on the determinants of reovirus susceptibility.

Introduction

Cancer is the leading cause of human death in developed countries and this number is projected to rise each year [1]. Even though precise estimates of global cancer morbidity and mortality rates in pets are unavailable due to the lack of census, cancer has also been ascertained to be a major cause of death in pets. Furthermore, there has been an upward trend in the number of pets dying of cancer, partly due to pets living to an increasingly older age and improved veterinary care [2]. Therefore, there is a dire need for more advanced and effective animal cancer therapy.

Over the last decade, one of the most interesting oncotherapies to have emerged is oncolytic virotherapy. Adenoviruses, herpes simplex viruses, vaccinia virus and reovirus are among the viruses that have shown promising results, up to the extent of phase II and III clinical trials in human cancers, including cancer of the liver, pancreas, prostate, ovaries, head and neck, glioma, melanoma and other solid tumors [3]. However, the use of oncolytic virotherapy in veterinary medicine is still far from becoming commercially available as promising laboratory results have yet to be translated into clinical outcomes. So far, canine cancers, such as osteosarcoma, malignant melanoma, lymphoma, soft tissue sarcoma, mammary adenoma and carcinoma, have been tested with only a few oncolytic viruses, mainly the human and canine adenoviruses, canine distemper virus (CDV) and vaccinia virus strains [4].

Reovirus, a small non-enveloped icosahedral virus with 10 segments of double stranded RNA, can be found ubiquitously and reovirus seropositivity is high among adults even though they may be asymptomatic [5]. Among the 3 reovirus serotypes, the potential of the serotype 3 Dearing strain has been extensively studied in a wide range of cancers [6–8]. Despite its popularity in human cancers, the effects of reovirus have not been tested in any naturally occurring animal cancer so far. Reovirus was first discovered as a naturally occurring replication-competent oncolytic virus when it infected and killed transformed cells but left normal cells unharmed [9]. Transformation of cell lines that were naturally resistant to reovirus with v-onk1, so or ra (all activators of Ras signaling pathway) allowed the cells to be highly susceptible to reovirus infection [10,11]. Phosphorylation of the PKR (dsRNA-activated protein kinase) has been identified to be one of the major factors that inhibited the translation of viral genes and viral replication in untransformed cells [11,12]. While Ras activation has been proven to enhance reolysis, further research has shown that reovirus can exert its oncolytic effects independent of this pathway [13]. This highlights the complexity of the mechanism in which reovirus works in cancer cells and that our current understanding of reovirus is far from complete.

* E-mail: mizutaku@yamaguchi-u.ac.jp

Citation: Hwang CC, Umeki S, Kubo M, Hayashi T, Shimoda H, et al. (2013) Oncolytic Reovirus in Canine Mast Cell Tumor. PLoS ONE 8(9): e73555. doi:10.1371/journal.pone.0073555

Copyright: © 2013 Hwang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing Interests: All authors have no potential conflicts of interest to disclose except that MC is the Chief Operating Officer of Oncolytics Biotech Inc. and has an ownership interest in that company. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Figure 1. Reovirus effectively exerts effect in MCT cell lines. (A) VIMC, CoMS, CM-MC, HRMC, RBL-2H3 and P815 cells in triplicate wells were either mock-infected or infected with reovirus at MOI 70. Human Burkitt's lymphoma cell lines, Daudi and Raji, were used as negative and positive controls respectively. After 72 hours post-infection (hpi), cell viability was assessed with 0.25% trypan blue. Data represents the mean and standard deviation of three independent experiments. *, p < 0.05 (by Student's t test). (B) Supernatant of reovirus-infected (MOI 70) MCT cell lines was harvested at 72 hpi before input and progeny virus titer were determined by TCID50 assay. Data represents the log10 mean viral yield and standard deviation from three independent experiments. *, p < 0.05 (by Student's t test). (C) Photomicrographs of mock-infected (upper panels) and reovirus-infected (MOI 70; lower panels) canine MCT cells taken at 72 hpi.

doi:10.1371/journal.pone.0073555.g001
UV)-inactivated virus was prepared by exposing live virus to UV through a collaborative effort. Ultraviolet grade reovirus; GMP) was obtained from OncolyticsTM Biotech Inc. (Calgary, Canada) as previously described [22] with modifications.

The same cell number of canine MCT cells was also used to assess the cell viability curve at 0, 24, 48 and 72 hpi at MOI 70 of reovirus. To assess the sensitivity of cells towards various titer of reovirus, the same cell number of canine MCT cells was incubated with UV-inactivated, 2.5, 14 and 70 MOI of reovirus for 72 hours before cell viability and titer of progeny virus were assessed.

Reovirus infectivity and Poly (ADP-Ribose) Polymerase cleavage (PARP)

Canine MCT cells were seeded at 5.0×10^5 and mock-infected or infected with reovirus at MOI 70 for 6 and 24 hours. The same number of control cells (Daudi and Raji) was mock-infected or infected with reovirus at MOI 70 and cells were harvested at 6, 24 and 48 hpi. Whole cell lysates for reovirus infectivity were treated with RIP A lysis buffer (50 mM Tris (pH7.5), 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate) while lysates for PARP cleavage were lysed with NP40 lysis buffer (1% NP40, 10 mM Tris HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA). Proteins were subjected to SDS-PAGE and Western blotting.

Measurement of cell death by propidium iodide (PI) staining

Canine MCT cells that were seeded at 1.0×10^5 were infected with reovirus at MOI 70 and cells were harvested at 48 and 72 hpi. Cells were washed with cold PBS and fixed with cold ethanol before storage at −20°C, pending analysis. Cells were incubated with 100 µl of 100 µg/ml Ribonuclease A (Nacalai Tesque, Kyoto, Japan) for 30 minutes before 4 µl of 1 mg/ml PI (Sigma-Aldrich Japan K.K., Tokyo, Japan) was added 5 minutes before acquisition. Flow cytometry was performed using CyFlow® Space (Partec GmbH, Munster, Germany) and results were analyzed using FlowJo software (Tree Star, Inc., San Carlos, CA, USA). The percentage of subG1 cells were considered as apoptotic cells.

Inhibition of reovirus cell killing by Z-VAD-FMK

To provide further evidence that reovirus-induced cell death was due to apoptosis, 2.5×10^5 cells were seeded in triplicate and pre-treated with control DMSO, 10 µM or 100 µM of Z-VAD-FMK (caspase inhibitor I; Calbiochem, Billerica, MA, USA) for 30 minutes at 37°C before being infected with reovirus at MOI 70. Viable and non-viable cells were assessed using 0.25% trypan blue at 48 hpi.

GST pull-down assay for Ras status

Ras activation status of each cell line was evaluated after GST pull-down [23]. To construct a vector that expresses GST fused with Ras-binding domain (RBD) of Raf-1, a part of Raf-1 gene encoding amino acids 1–149 of Raf-1 was amplified using plasmid pCMV5 Raf-1 as a template and primers YT M647 (5’ CGTGGA_TCCGAGCACA TACAAGGGACT 3’, underline indicates the BamHI site) and YT M648 (5’ CCGGAAATT CAGGCTCAGGAACTCTT 3’, underline indicates the EcoRI site) as previously described [24]. The amplified PCR products were subcloned into the BamHI and EcoRI sites of the pGEX 4T-3 vector (pGEX-RBD#2). JM109 was transformed with pGEX-RBD#2 and GST-RBD was extracted with lysis buffer. Cytoplasmic extract from cells (300 µg) was mixed with glutathione-Sepharose 4B beads (GE Healthcare, Tokyo, Japan) conjugated with GST-RBD protein for 1 hour before washing with lysis

Materials and Methods

Ethics statement

All animal procedures were conducted in accordance to the Yamaguchi University Animal Care and Use guidelines and were approved by the Institutional Animal Care and Use Committee of Yamaguchi University (Permit Number: 188). All efforts were made to ensure minimal pain and suffering of the animals.

Cell cultures and reovirus

Four established canine MCT cell lines, VIMC, CoMS, CM-MC and HRMC, were used in this study. VIMC [19] and CoMS [20] were derived from viscerai MCT while CM-MC [19] and HRMC [21] were MCT of cutaneous origin. RBL-2H3, a rat basophilic leukemia cell line, and P815, a mouse lymphoblast-like mastocytoma cell line, were selected as comparison models of mast cell across species while the human Burkitt’s lymphoma cell lines, Daudi and Raji, were used as negative and positive controls respectively [6]. Mouse L929 fibroblastic cell line was used in the titration of progeny virus. RBL-2H3, P815, Raji and L929 were obtained from the Cell Resource Center for Biomedical Research (Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan). All cells were maintained in R10 complete medium (RPMI1640 supplemented with 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin and 55 mM 2-mercaptoethanol) kept at 37°C in a humidified 5% CO2 incubator.

The Dearing strain of reovirus serotype 3 (Reolyxin®, clinical grade reovirus; GMP) was obtained from Oncolytics™ Biotech Inc. (Calgary, Canada) through a collaborative effort. Ultraviolet (UV)-inactivated virus was prepared by exposing live virus to UV light for 90 minutes.

Reovirus infection of cell lines

VIMC, CoMS, CM-MC, HRMC, Daudi and Raji were seeded at 2.5×10^5 cells while RBL-2H3 and P815 were seeded at 1.25×10^5 cells before being mock-infected or infected with reovirus at multiplicity of infection (MOI) of 70 plaque-forming units (PFUs) per cell. All cells were seeded in triplicates in 48-well plates. Cells were stained with 0.25% trypan blue and viability counted via hemocytometer at 72 hours post-infection (hpi).
buffer. Precipitated Ras-GTP and whole cell lysates were subjected to SDS-PAGE, followed by Western blotting.

Western blotting
Following electrophoresis, proteins were transferred to polyvinylidene fluoride (PVDF) membranes and probed with specific primary antibodies as follows: rabbit anti-reovirus (produced by our lab), rabbit anti-PARP (NeoMarkers, Fremont, CA, USA) or mouse anti-pan-Ras (Calbiochem). Incubation with primary antibodies was followed by secondary labeling using goat anti-rabbit or goat anti-mouse IgG HRP (Zymed Laboratories, San Francisco, CA, USA). The membranes were visualized by immersion in Western Lightning Chemiluminescence reagent (PerkinElmer, Shelton, CT, USA). Immunoreactive bands were visualized using the Luminescent Image Analyzer LAS 3000 mini (FUJIFILM, Tokyo, Japan) and analyzed using Science Lab 2005 (FUJIFILM). Membranes were stripped between antibody staining procedures with stripping buffer (100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris (pH6.7)) for 30 minutes at 60°C. Goat anti-actin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and rabbit anti-goat IgG HRP (Bethyl Laboratories, Inc., Montgomery, TX, USA) were used as loading controls.

Figure 2. Reovirus infectivity and replication in MCT cell lines. (A) Cell viability of reovirus-infected (MOI 70) canine MCT cell lines were assessed with 0.25% trypan blue at 0, 24, 48 and 72 hpi. (B) Canine MCT cell lines were treated with UV-inactivated, 2.8, 14 and 70 MOI of reovirus and cell viability was assessed with 0.25% trypan blue at 72 hpi. (C) Input and progeny virus titer of supernatant from reovirus-infected MCT cell lines at various MOI were determined by TCID₅₀ assay. Data represents the mean and standard deviation of three independent experiments. (D) Whole cell lysates of reovirus-infected (MOI 70) of cell lines at 6 and 24 hpi (48 hpi only for Daudi and Raji) were prepared before proteins were separated using SDS-PAGE electrophoresis. Presence of µ and σ outer capsid proteins was determined using rabbit polyclonal anti-reovirus antibody. β-actin was used as protein loading controls.
doi:10.1371/journal.pone.0073555.g002
Subcutaneous tumor xenograft models in NOD/SCID mice

Eight to nine-week-old NOD/ShiJic-scid (NOD/SCID) mice were obtained from Kyudo Co. Ltd. (Saga, Japan) and studies were conducted in a specific pathogen-free area in accordance with the Yamaguchi University Animal Care and Use guidelines. VIMC or CoMS cells (1.0 x 10^7 in 50 μl PBS) were implanted subcutaneously into one or both flanks of the mice under general anesthesia. When the desirable tumor size was achieved on either side, 7.0 x 10^7 PFUs of live reovirus (experimental group) or UV-inactivated reovirus (control group) in 20 μl PBS were injected.
intratumorally. Two-dimensional tumor measurements were performed with a caliper every other day until euthanasia due to excessive tumor burden. Tumor measurements were analyzed and shown as tumor mass (mm³). Tumors and remaining masses were fixed in 10% neutral buffered formalin and embedded in paraffin before staining with hematoxylin and eosin (H&E) for histopathological analysis.

For immunohistochemical (IHC) staining, deparafinized samples were treated with Target Retrieval Solution (Dako, Glostrup, Denmark) before treatment with 3% hydrogen peroxidase and Protein Block (Dako). Sections were then incubated with rabbit anti-reovirus polyclonal antibody (1:500 dilution; produced by our lab), followed by Histofine Simple Stain MAX-PO (R) (Nichirei Biosciences, Inc., Tokyo, Japan). Slides were subjected to 3,3-diaminobenzidine tetrachloride (Roche Diagnostics K.K., Tokyo, Japan) staining before counterstaining with Meyer’s hematoxylin.

Reovirus infection of primary canine MCT samples
Primary canine MCT tumor cells were obtained by fine needle aspiration (FNA) from canine patients with confirmed diagnosis of MCT at the Yamaguchi University Animal Medical Center. Immediately after collection, 2.5×10⁴ cells were seeded in triplicate before being mock-infected or infected with reovirus at MOI 70. Viability of cells was assessed at 72 hpi with 0.25% trypan blue and progeny virus was measured using TCID₅₀ assay.

Generation of canine and murine bone marrow-derived cultured mast cells (BMCMC)
Canine BMCMC was isolated and purified from bone marrow cells of two healthy beagles as previously reported [25,26]. Briefly, bone marrow cells were separated using Lymphoprep™ kit (Axis-Shield PoC AS, Oslo, Norway) before CD34⁺ cells were enriched using MidiMACS (Miltenyi, Auburn, CA, USA) separator. CD34⁺ cells were cultured in Stemline II (Sigma-Aldrich) supplemented with 100 ng/ml recombinant canine stem cell factor (rcSCF; R&D Systems, Minneapolis, MN, USA) and incubated at 37°C in a humidified 5% CO₂ incubator. Matured CD117⁺ cells were enriched with MidiMACS separator again 4 weeks after culture.

Murine BMCMC was generated from bone marrow cells of C57BL/6N mice (Kyudo Co. Ltd.) and cultured in D10 (DMEM with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin and 55 μM 2-mercaptoethanol) supplemented with murine IL-3 (PeproTech Inc., Rocky Hill, NJ, USA) [27]. Cultures were grown at 37°C in a humidified 5% CO₂ incubator for 5 weeks before CD117⁺ cells were enriched with MidiMACS separator.

Purity of canine and murine BMCMC were confirmed with toluidine blue staining after attaching BMCMC on glass slides using cytospin and fixing in Carnoy’s solution for 30 minutes. Both canine and murine BMCMC were seeded in triplicate before being mock-infected or infected with reovirus at MOI 70 and cell viability was assessed at 72 hpi with 0.25% trypan blue. Progeny virus produced was titered using TCID₅₀ assay.
Results

MCT cell lines are susceptible to reovirus-induced cytotoxicity in vitro

The susceptibility of MCT cell lines to reovirus infection and oncolysis was first examined with MOI 70 of reovirus and cell viability was assessed at 72 hpi. All MCT cell lines, especially the canine MCT cell lines, were susceptible to reovirus (Fig. 1A; p<0.05). At 72 hpi, 100% cell death was induced in VIMC, CoMS and CM-MC and more than 80% was induced in HRMC. Reovirus-infected P815 showed a higher percentage of cell death in comparison to RBL-2H3. Cell viability was also reduced (p<0.05) in Raji, but not in Daudi.

Following reovirus infection, P815, VIMC, CoMS, CM-MC, HRMC and Raji produced a significant amount of progeny virus at 72 hpi, while Daudi did not (Fig. 1B). This indicates that...
Reovirus is able to replicate in susceptible cell lines and infectious progeny virus is released for subsequent infection cycles. Even though progeny virus was produced in RBL-2H3, the amount was not significantly higher than the input titer. Data from MCT 1 (A, B) represents the mean and standard deviation three independent experiments while two independent experiments were conducted for MCT 2 (C, D). *p < 0.05 (by Student's t test).

doi:10.1371/journal.pone.0073555.g007

Reovirus induces apoptosis in MCT cell lines

Confirmation of cell death in canine MCT cell lines was subsequently assessed with PI staining. An increment in the proportion of the subG1 cells indicated that the number of apoptotic cells increased from 48 to 72 hpi. At 72 hpi, more than 95% cell death was seen in VIMC and CoMS, 75% in CM-MC and 48% in HRMC (Fig. 3A). The consistency of these results indicates that although trypan blue is usually used as a fast and easy screening of cell viability, it is a reliable technique to directly display the proportion of viable and non-viable cells.

Western blot analysis of PARP cleavage in the canine MCT cell lines confirmed the appearance of the signature cleavage product as early as 6 hpi in VIMC and CoMS. Cleaved PARP was visualized in all the canine MCT cell lines at 24 hpi as compared to the mock-infected samples (Fig. 3B). The cleavage of cellular substrate PARP in reovirus-infected cells demonstrated the morphological hallmark of apoptosis.

Canine MCT cell lines were also pre-treated with Z-VAD-FMK before infection with reovirus and cell viability was determined at 48 hpi. Reovirus-induced cytotoxicity was reversed by Z-VAD-FMK in all the cell lines where cell death was slightly inhibited at 48 hpi. The combination of these results allows us to conclude that reovirus induces canine MCT cell death predominantly through an apoptotic pathway.

Ras is not activated in MCT cell lines

Ras activation has been reported to contribute to proteolytic reovirus disassembly as well as increased progeny virus infectivity and release [28]. Since reovirus has not been tested in any canine cancer, it remains unclear if the Ras signaling pathway plays a role in reovirus susceptibility in these cells. Using Raji as the standard of Ras activation, our results showed that P815 and HRMC have elevated Ras activity, while RBL-2H3, VIMC, CoMS and CM-MC did not (Fig. 4). Even though all of the MCT cell lines were susceptible to reovirus, the level of activated Ras expression varied. The notion that reovirus susceptibility is dependent on the Ras activation status is inconsistent, especially when compared to the three canine MCT cell lines that are the most susceptible to the effects of reovirus. This finding indicates that reovirus exerts its potent oncolytic effects in MCT cell lines independent of the Ras signaling pathway.

Reovirus induces regression of MCT mass in vivo

To assess the therapeutic potential of reovirus in vivo, VIMC and CoMS unilateral subcutaneous xenograft models were established in NOD/SCID mice and treated with a single intratumoral of reovirus injection. All mice treated with reovirus experienced
significant regression of tumor mass by day 4 post-treatment for VIMC and by day 6 post-treatment for CoMS (Fig. 5A and 5B; \(p < 0.05\)). However, black tail syndrome, a possible side effect in reovirus-infected NOD/SCID mice [29], was observed in one out of five in VIMC and three out of five in CoMS-transplanted mice that were treated with reovirus.

Anticipating that reovirus-susceptible tumor would allow generation of adequate progeny virus for hematogenous dissemination, bilateral cutaneous VIMC xenograft models were created and treated with a single unilateral intratumoral reovirus injection on either mass. As expected, significant tumor regression was not only limited to the intratumoral-treated tumor, but was also observed in the non-treated contralateral tumor (Fig. 6A; \(p < 0.05\)). This suggests that a substantial amount of reovirus was produced and released from the treated tumor into the blood circulation. No side effects were observed in this group of mice.

In contrast to the UV-inactivated reovirus treated tumors (Fig. 6B), H&E-stained histopathological samples from the bilateral VIMC xenograft models showed extensive necrotic lesions within reovirus-treated tumors (Fig. 6C), confirming the presence of anti-cancer activity. Similar extensive necrotic lesions were also seen in the histopathological samples of the unilateral xenograft models (data not shown). IHC staining demonstrated the presence of reovirus proteins only in the reovirus-treated and the contralateral tumors (Fig. 6C).

Primary canine MCT, normal canine and murine BMCMC are susceptible to reovirus

The next step of our study was to determine reovirus oncolysis in primary canine MCT samples. Reovirus induced approximately 80% cell death in both the primary MCT samples tested and an increased amount of progeny virus was produced (Fig. 7). This strongly supports the feasibility of using reovirus as a potential therapeutic option in cases of canine MCT.

To assess the effects of reovirus in normal mast cells, canine and murine BMCMC were generated and infected with reovirus. Cell viability was markedly reduced in the canine BMCMC (\(~90\%\) cell death) (Fig. 8A) as compared to the murine BMCMC (\(~40\%\) cell death) (Fig. 8C). Consequently, reovirus-infected canine BMCMC produced a higher titer of progeny virus as compared to murine BMCMC.
Discussion

Reovirus has been extensively studied in human oncology over the past decade. Due to the relative similarities between human and canine cancers, we hypothesized that the cytotoxic effects of reovirus could be exploited in canine cancers as well. To our knowledge, this is the first report of the effects of reovirus in veterinary oncology, where the susceptibility of canine MCT in vitro, in vivo and ex vivo towards the oncolytic effects of reovirus was determined. We demonstrated that MCT cell lines are susceptible to reovirus, especially in canine MCT. Moreover, these in vitro findings were confirmed in vivo, whereby LaMC and CoMS subcutaneous tumors underwent marked regression after a single intratumoral reovirus injection. The susceptibility of primary canine MCT cells towards reovirus further supported our hypothesis. We also discovered that normal mast cells derived from bone marrow of dogs and mice are susceptible to reovirus.

Up till now, the key mechanism that determines reovirus susceptibility has not yet been ascertained. Previous report suggests that the Ras signaling pathway plays a vital role in enhancing reovirus disassembly, infectivity and release of progeny virus [28]. Our data, however, strongly suggests that the susceptibility of MCT cell lines does not correlate with the level of activated Ras expression. This was evident in the three canine MCT cell lines that were the most susceptible to reovirus but did not have any activated Ras expression. On the other hand, reovirus did not have such a dramatic effect on HRMC and P815 even though they expressed a high level of activated Ras. Even though a concrete conclusion could not be made due to the limited number of cell lines examined, it is possible that there is a negative correlation between Ras activation and reovirus susceptibility. This negative correlation was also suggested by Twigger et al., where the oncolytic effects of reovirus was shown to be independent of the epidermal growth factor receptor (EGFR)/ Ras signaling pathway in head and neck cancer cell lines [13]. Furthermore, the lack of association between reovirus susceptibility and the Ras signaling pathway has also been reported in human hematopoietic cancers [30], colon cancer [31] and non-small cell lung cancer [32]. Moreover, it is known that the ras mutation in canine tumors is rare [16,17]. Thus, it was not surprising that three out of four canine MCT cell lines that were susceptible to reovirus did not have an activated Ras signaling pathway.

Research on reovirus over the past decade have shown that it is very unlikely that the susceptibility of tumor cells towards reovirus lies solely on the simple generic activation of Ras [33–39]. Reovirus triggers apoptosis in a caspase-dependent manner [40], which is also reported in this study. Other reports have indicated that reovirus induces apoptosis via the activation of cellular stress kinase, c-Jun N-terminal kinase and nuclear factor kappa B (40,41). Hence, there is a possibility that one of these pathways might be the key determinant of reovirus susceptibility.

So far, KIT, a receptor tyrosine kinase, has been the best-described molecular abnormality in canine MCT [15]. Normally expressed on cells such as hematopoietic stem cells, melanocytes and mast cells, KIT regulates apoptosis, cell differentiation, proliferation, chemotaxis and cell adhesion after being activated by stem cell factor [42]. KIT has also been reported to play an equally important role in various human cancers [43]. All of the canine MCT cell lines used in this study have aberrant autophosphorylation of the c-Kit receptor where VIMC, CoMS and CM-MC have KIT mutations and HRMC has a SCF/c-Kit receptor autocrine mechanism [44]. Since all the canine MCT cell lines are susceptible to reovirus, we speculated that the aberrant autophosphorylation of the c-Kit receptor might somehow be involved. However, from this study, we discovered that normal canine and murine mast cells are susceptible to reovirus. Therefore, it is unlikely that the c-Kit receptor contributes to reovirus-induced cell death.

On top of that, the finding that normal mast cells are susceptible to reovirus contradicts the belief that oncolytic viruses only infect and kill cancerous cells while leaving normal cells unharmed in a selective fashion. In a recent report [45], normal mature cells, mainly the peripheral blood mononuclear cells (PBMCs), granulocytes and platelets, were found to be involved in reovirus delivery to the target cancer cells. Normal cells, such as dendritic cells, have also been cited to play an important role in transportation of reovirus to the target tumor cells in order to evade the antiviral immune response [46]. However, this phenomenon does not involve reovirus replication in the dendritic cells [47]. In our study, reovirus replication occurred in normal mast cells but the mechanisms remain unknown. Nonetheless, there is no data to suggest that reovirus poses a significant danger to dogs or other mammals. The safety implications and virus shedding after intentional reovirus infection in dogs are currently under investigation.

The host immune system is an important factor that will dictate the outcome of virotherapy. Unfortunately, unlike in the human population, limited data is available regarding reovirus infection and antibody production in dogs [48–50]. Therefore, prediction of the effects of pre-existing neutralizing antibodies in reovirus therapy in dogs is difficult. Immunocompromised mouse models were also used in this study and therapeutic response might be different in immunocompetent hosts. However, the efficacy of oncolytic virotherapy in immunocompetent models has been well documented [51]. Instead of limiting therapy, reovirus have been reported to stimulate the innate and adaptive immune response against tumor cells, acting as immunotherapy to amplify the anti-tumor effects [33,47,51]. Nevertheless, the correlation between these laboratory results and the therapeutic efficacy of reovirus in a clinical setting has yet to be established. Therefore, clinical trials in canine MCT patients are necessary to establish the efficacy of reovirus in canine cancers and to evaluate the extent of immune system involvement.

Conclusion

The feasibility of reovirus therapy in canine MCT is evident with the in vitro, in vivo and ex vivo data obtained in this study. However, there remains a need to clarify the mechanism behind the cytotoxic effects of reovirus in canine MCT as blind usage of reovirus could have disastrous consequences. In summary, as in human cancers, reovirus has great potential as a next generation therapeutic option in veterinary oncology.

Acknowledgments

We thank Drs. Takayuki Nakagawa and Hajime Tsujimoto for providing the cell lines for this study. We thank Drs. Keitaro Ohmori and Shinpei Kawarai for technical advice.

Author Contributions

Conceived and designed the experiments: CCH MO TM. Performed the experiments: CCH TM MK. Analyzed the data: CCH MK TH. Contributed reagents/materials/analysis tools: SU HS MM KM KB HH MC. Wrote the paper: CCH.


References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA: A cancer journal for clinicians 61: 69–90.

2. Butler LM, Bennett BN, Page RJ. (2013) Epidemiology and the evidence-based medicine approach. In: Withrow SJ, Vail DM, Page RJ, editors. Small animal clinical oncology. Missouri: Elsevier Saunders. pp. 68–82.

3. Meerehi S, Yao Y (2010) Oncolytic viruses in cancer therapy. Eur J Sci Res 40: 156–171.

4. Patel SS, Gentschev I, Nolte I, Ogilvie G, Szalay AA (2012) Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients. J Transl Med 10: 3.

5. Selb B, Weber B (1994) A study of human reovirus IgG and IgA antibodies by ELISA and western blot. J Virol Methods 47: 15–25.

6. Alain T, Hirasaki K, Pon KJ, Nishimura SG, Urbanek SJ, et al. (2002) Reovirus therapy of lymphoid malignancies. Blood 100: 4146–4153.

7. Thirumukumanam CM, Nodwell MJ, Hirasaki K, Shiu ZQ, Diaz R, et al. (2010) Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res 70: 2435–2444.

8. Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, et al. (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 17: 581–588.

9. Duncan SR, Stansell SM, Cox DC (1978) Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 28: 444–449.

10. Strong JE, Lee PW (1996) The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 70: 612–616.

11. Strong JE, Coffey MC, Tang D, Salminen P, Lee PW (1998) The molecular basis of viral oncology: usurpation of the Ras signaling pathway by reovirus. EMBO J 17: 3351–3362.

12. Coffey MC, Strong JE, Forsyth PA, Lee PW (1998) Regulation of normal and neoplastic human mast cell development in mastocytosis. Trans Am Clin Climatol Assoc 116: 105–205.

13. London CA, Thamm DH (2013) Mast cell tumors. In: Withrow SJ, Vail DM, Page RJ, editors. Small animal clinical oncology. Missouri: Elsevier Saunders. pp. 353–355.

14. Wataneg F, Mayr B, Gamanith R, Vetter C, Lion T, et al. (2001) A study of human reovirus IgG and IgA antibodies by ELISA and western blot. J Virol Methods 47: 15–25.

15. Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, et al. (2002) Reovirus therapy of lymphoid malignancies. Blood 100: 4146–4153.

16. Thirumukumanam CM, Nodwell MJ, Hirasaki K, Shiu ZQ, Diaz R, et al. (2010) Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res 70: 2435–2444.

17. Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, et al. (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 17: 581–588.

18. Duncan SR, Stansell SM, Cox DC (1978) Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 28: 444–449.

19. Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanek SJ, et al. (2002) Reovirus therapy of lymphoid malignancies. Blood 100: 4146–4153.

20. Thirumukumanam CM, Nodwell MJ, Hirasaki K, Shiu ZQ, Diaz R, et al. (2010) Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res 70: 2435–2444.

21. Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, et al. (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 17: 581–588.

22. Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanek SJ, et al. (2002) Reovirus therapy of lymphoid malignancies. Blood 100: 4146–4153.

23. Taylor SJ, Resnick RJ, Shalloway D (2001) Nonradioactive determination of Ras-GTP levels using activated ras interaction assay. Meth Enzymol 333: 333–342.

24. Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, et al. (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 17: 581–588.